Literature DB >> 16823825

Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution.

Ming-Yuan Lee1, Tran-Der Tan, An-Chen Feng, Mei-Ching Liu.   

Abstract

The clinicopathological characteristics of malignant lymphomas vary according to geography. The purpose of this study is to determine the distribution and clinicopathological characteristics of malignant lymphomas in Taiwan. Archival tissue from 598 malignant lymphomas during the period of 1995-2002 was retrieved. They were reclassified according to the World Health Organization classification system. Clinical data, including age, gender, clinical staging, and follow-up, were scrutinized. There were 330 males and 268 females. The median age at onset of disease was 56 years for B-cell lymphoma (BCL), 50 years for T/NK-cell lymphoma (TCL), and 26 years for Hodgkin's lymphoma (HL). BCL accounted for 80.6%, TCL for 12.4%, and HL for 7%. The major subtypes of non-HL were diffuse large B-cell lymphoma, follicular lymphoma, plasma cell myeloma, marginal zone lymphoma of mucosa-associated lymphoid tissue type, mantle cell lymphoma, unspecified peripheral TCL, and nasal type T/NK-cell lymphoma. Nodular sclerosing subtype was the most common in HL. The frequencies of TCL and HL were relatively low. For histological subtype, enteropathy-type TCL and primary bone marrow HL had higher frequency and poorer prognosis. The 5-year overall survival of BCL, TCL, and HL was 58.9, 34.7, and 83.5%, respectively. To the best of our knowledge, this is the largest series study of malignant lymphoma in Taiwan. Immunophenotype, histological subtype, and clinical stage play significant roles in prognosis (P < 0.05).

Entities:  

Mesh:

Year:  2006        PMID: 16823825     DOI: 10.1002/ajh.20649

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  10 in total

1.  Angioimmunoblastic T-cell lymphoma in Taiwan shows a frequent gain of ITK gene.

Authors:  Peir-In Liang; Sheng-Tsung Chang; Ming-Yen Lin; Yen-Chuan Hsieh; Pei-Yi Chu; Chih-Jung Chen; Kai-Jen Lin; Yun-Chih Jung; Wei-Shou Hwang; Wen-Tsung Huang; Wei-Chin Chang; Hongtao Ye; Shih-Sung Chuang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

2.  Mice hypomorphic for Atr have increased DNA damage and abnormal checkpoint response.

Authors:  Ryan L Ragland; Martin F Arlt; Elizabeth D Hughes; Thomas L Saunders; Thomas W Glover
Journal:  Mamm Genome       Date:  2009-06-07       Impact factor: 2.957

3.  Aberrant antigenic expression in extranodal NK/T-cell lymphoma: a multi-parameter study from Thailand.

Authors:  Tawatchai Pongpruttipan; Tanawan Kummalue; Anan Bedavanija; Archrob Khuhapinant; Koichi Ohshima; Fumiko Arakawa; Daisuke Niino; Sanya Sukpanichnant
Journal:  Diagn Pathol       Date:  2011-08-25       Impact factor: 2.644

4.  Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution.

Authors:  Qun-Pei Yang; Wen-Yan Zhang; Jian-Bo Yu; Sha Zhao; Huan Xu; Wei-Ya Wang; Cheng-Feng Bi; Zhuo Zuo; Xiao-Qing Wang; Juan Huang; Lin Dai; Wei-Ping Liu
Journal:  Diagn Pathol       Date:  2011-08-22       Impact factor: 2.644

5.  Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma.

Authors:  Claire Wen-Chi Yang; Chun-Wei Wang; Ruey-Long Hong; Chiao-Ling Tsai; Ming Yao; Jih-Luh Tang; Chung-Wu Lin; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  J Radiat Res       Date:  2016-08-16       Impact factor: 2.724

6.  How useful is bone marrow study as an initial investigative tool without lymph node biopsy in malignant lymphoma?: Eleven years of experience at a single institution.

Authors:  Woo-Jae Kwoun; Jeong-Yeal Ahn; Pil-Whan Park; Yiel-Hea Seo; Kyung-Hee Kim; Ja Young Seo; Hwan Tae Lee; Kuai-Han Yoo
Journal:  J Clin Lab Anal       Date:  2019-02-06       Impact factor: 2.352

7.  A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan.

Authors:  Sung-Nan Pei; Yanfang Liu; Ming-Chung Wang; Ming-Chun Ma; Ching-Yuan Kuo; Chun-Kai Liao; Hong Qiu; Lee Anne Rothwell
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

8.  Stem cell transplant for mantle cell lymphoma in Taiwan.

Authors:  Yu-Hung Wang; Ching-Yun Hsieh; Liang-Tsai Hsiao; Tung-Liang Lin; Yi-Chang Liu; Ming Yao; Tran-Der Tan; Bor-Sheng Ko
Journal:  Sci Rep       Date:  2022-04-05       Impact factor: 4.379

9.  Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Authors:  Jie Jin; Rumiko Okamoto; Sung-Soo Yoon; Lee-Yung Shih; Jun Zhu; Ting Liu; Xiaonan Hong; Lixia Pei; Brendan Rooney; Helgi van de Velde; Huiqiang Huang
Journal:  Onco Targets Ther       Date:  2018-07-06       Impact factor: 4.147

Review 10.  Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group.

Authors:  Dok Hyun Yoon; Junning Cao; Tsai-Yun Chen; Koji Izutsu; Seok Jin Kim; Yok Lam Kwong; Tong Yu Lin; Lim Soon Thye; Bing Xu; Deok Hwan Yang; Won Seog Kim
Journal:  J Hematol Oncol       Date:  2020-03-17       Impact factor: 17.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.